The Use of N-Terminal-Pro-BNP in Preterm Infants
- PMID: 20069108
- PMCID: PMC2804037
- DOI: 10.1155/2009/175216
The Use of N-Terminal-Pro-BNP in Preterm Infants
Abstract
The use of natriuretic peptides in the neonatal population is emerging. B-type Natriuretic Peptide (BNP) and N-terminal-Pro-BNP (NTpBNP) are used in the adult population to assess myocardial function and volume loading. Their role in prognosis following cardiac surgery has also been identified. In preterm infants NTpBNP is becoming increasingly recognised as a potential screening tool for patent ductus arteriosus (PDA), and a marker for myocardial performance. In addition, NTpBNP may provide prognostic information in preterm infants and term infants with congenital diaphragmatic hernia (CDH). In this paper, the role of NTpBNP in the preterm population will be discussed.
Similar articles
-
B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.Acta Paediatr. 2015 Apr;104(4):e139-42. doi: 10.1111/apa.12892. Epub 2015 Feb 4. Acta Paediatr. 2015. PMID: 25488470
-
Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage.Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F407-12. doi: 10.1136/adc.2007.133140. Epub 2008 Feb 19. Arch Dis Child Fetal Neonatal Ed. 2008. PMID: 18285375
-
Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants.Arch Dis Child Fetal Neonatal Ed. 2011 Mar;96(2):F133-7. doi: 10.1136/adc.2010.185967. Epub 2010 Nov 11. Arch Dis Child Fetal Neonatal Ed. 2011. PMID: 21071684
-
Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants.Early Hum Dev. 2017 Feb;105:41-47. doi: 10.1016/j.earlhumdev.2016.12.007. Epub 2016 Dec 18. Early Hum Dev. 2017. PMID: 27998626 Review.
-
Patent ductus arteriosus in preterm infants.Indian Pediatr. 2011 Apr;48(4):301-8. doi: 10.1007/s13312-011-0062-5. Indian Pediatr. 2011. PMID: 21532100 Review.
Cited by
-
NT-proBNP, to be or not to be a BPD biomarker?Pediatr Res. 2024 Oct 31. doi: 10.1038/s41390-024-03681-8. Online ahead of print. Pediatr Res. 2024. PMID: 39482496 No abstract available.
-
Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. doi: 10.1002/14651858.CD013129.pub2. Cochrane Database Syst Rev. 2022. PMID: 36478359 Free PMC article.
-
Patent ductus arteriosus in preterm infants: is early transcatheter closure a paradigm shift?J Perinatol. 2019 Nov;39(11):1449-1461. doi: 10.1038/s41372-019-0506-7. Epub 2019 Sep 27. J Perinatol. 2019. PMID: 31562396 Review.
-
Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation.BMC Pediatr. 2019 Sep 13;19(1):333. doi: 10.1186/s12887-019-1708-z. BMC Pediatr. 2019. PMID: 31519154 Free PMC article.
-
Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?Children (Basel). 2022 Jul 3;9(7):1002. doi: 10.3390/children9071002. Children (Basel). 2022. PMID: 35883986 Free PMC article.
References
-
- Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of Pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochemical and Biophysical Research Communications. 1995;214(3):1175–1183. - PubMed
-
- Maack T. Receptors of atrial natriuretic factor. Annual Review of Physiology. 1992;54:11–27. - PubMed
-
- Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacology and Therapeutics. 2004;102(3):223–241. - PubMed
LinkOut - more resources
Full Text Sources